UBS Group’s Cyclo Therapeutics, Inc. Warrant CYTHW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-175
| Closed | -$13 | – | 10946 |
|
|
2024
Q4 | $13 | Buy |
+175
| New | +$28 | ﹤0.01% | 9801 |
|
|
2024
Q2 | – | Sell |
-81
| Closed | -$19 | – | 10263 |
|
|
2024
Q1 | $19 | Buy |
+81
| New | +$24 | ﹤0.01% | 9042 |
|
|
2023
Q2 | – | Sell |
-20
| Closed | -$4 | – | 9830 |
|
|
2023
Q1 | $4 | Sell |
20
-225
| -92% | -$67 | ﹤0.01% | 9501 |
|
|
2022
Q4 | $127 | Sell |
245
-792
| -76% | -$467 | ﹤0.01% | 10372 |
|
|
2022
Q3 | $0 | Hold |
1,037
| – | – | ﹤0.01% | 11075 |
|
|
2022
Q2 | $1K | Sell |
1,037
-109
| -10% | -$107 | ﹤0.01% | 10009 |
|
|
2022
Q1 | $2K | Sell |
1,146
-328
| -22% | -$586 | ﹤0.01% | 9694 |
|
|
2021
Q4 | $3K | Sell |
1,474
-596
| -29% | -$1.44K | ﹤0.01% | 9705 |
|
|
2021
Q3 | $5K | Buy |
2,070
+1,865
| +910% | +$6.75K | ﹤0.01% | 8570 |
|
|
2021
Q2 | $1K | Sell |
205
-788
| -79% | -$2.91K | ﹤0.01% | 9207 |
|
|
2021
Q1 | $4K | Sell |
993
-855
| -46% | -$3.27K | ﹤0.01% | 8441 |
|
|
2020
Q4 | $2K | Buy |
+1,848
| New | +$2.28K | ﹤0.01% | 8131 |
|
UBS Group's CYTHW Position: Q1 2025 in Review
UBS Group sold out of Cyclo Therapeutics, Inc. Warrant (CYTHW) in Q1 2025, closing a stake of 175 shares — an estimated $13 sold.
UBS Group first reported a position in CYTHW in Q4 2020 and held it in 12 quarters. The position peaked at $5K in Q3 2021. 0 funds tracked by Wall St. Rank hold CYTHW as of Q1 2025.
- UBS Group reported no remaining Cyclo Therapeutics, Inc. Warrant position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 175 Cyclo Therapeutics, Inc. Warrant shares in Q1 2025, an estimated $13.
- UBS Group first reported a position in Cyclo Therapeutics, Inc. Warrant in Q4 2020 and held it in 12 quarters.
- UBS Group's Cyclo Therapeutics, Inc. Warrant position peaked at $5K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Warrant as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.